IPP Bureau

Mapmygenome launches Genomics Experience Centre in Bengaluru
Mapmygenome launches Genomics Experience Centre in Bengaluru

By IPP Bureau - March 02, 2022

At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors

SeQuent Scientific completes acquisition of Nourrie in Brazil
SeQuent Scientific completes acquisition of Nourrie in Brazil

By IPP Bureau - March 02, 2022

Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%

Dr Julie L. Gerberding to retire from Merck as Chief Patient Officer
Dr Julie L. Gerberding to retire from Merck as Chief Patient Officer

By IPP Bureau - March 02, 2022

Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16

Amrita University launches wearable device for home monitoring of glucose and BP
Amrita University launches wearable device for home monitoring of glucose and BP

By IPP Bureau - March 02, 2022

Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home

Univar Solutions opens latest Solution Centre for its global ecosystem of innovation
Univar Solutions opens latest Solution Centre for its global ecosystem of innovation

By IPP Bureau - March 02, 2022

State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond

USFDA approves first generic version of Apokyn cartridges
USFDA approves first generic version of Apokyn cartridges

By IPP Bureau - March 02, 2022

TruPharma has commenced commercial marketing of Sage's approved generic cartridge product

Amneal enters U.S. biosimilars market with approval of Releukotm
Amneal enters U.S. biosimilars market with approval of Releukotm

By IPP Bureau - March 02, 2022

First of three Amneal biosimilars expected for U.S. approval and launch in 2022

Serina Fischer appointed GM India at Takeda Pharmaceuticals
Serina Fischer appointed GM India at Takeda Pharmaceuticals

By IPP Bureau - March 02, 2022

Serina has over 17 years of experience in the biopharmaceutical industry

Trivitron Healthcare acquires U.S. based The Kennedy Company
Trivitron Healthcare acquires U.S. based The Kennedy Company

By IPP Bureau - March 02, 2022

This has further strengthened its manufacturing presence in the United States of America

Singapore first to top WHO’s classification of medical regulator
Singapore first to top WHO’s classification of medical regulator

By IPP Bureau - March 01, 2022

Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference

Medvarsity partners with Clove Dental to launch Fellowship in Endodontics
Medvarsity partners with Clove Dental to launch Fellowship in Endodontics

By IPP Bureau - March 01, 2022

110 BDS graduates admitted in week one of the launch

Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review
Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review

By IPP Bureau - March 01, 2022

If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.

Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period

By IPP Bureau - March 01, 2022

High level of vaccine efficacy maintained over a 6-month period of surveillance

Boehringer Ingelheim partners with Lifebit to capture health data
Boehringer Ingelheim partners with Lifebit to capture health data

By IPP Bureau - March 01, 2022

This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine

AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006

By IPP Bureau - March 01, 2022

Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m

Latest Stories

Interviews

Packaging